MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.
Realizing the basis for generating long-lasting clinical responses in cancer patients after therapeutic vaccinations provides the means to further ameliorate clinical efficacy. Peptide cancer vaccines stimulating CD4(+) T helper cells are often promising for inducing immunological memory and persistent CD8(+) cytotoxic T cell responses. Recent reports from our clinical trial with the AE37 vaccine, which is a HER2 hybrid polypeptide, documented its efficacy to induce CD4(+) T cell immunity, which was associated with clinical improvements preferentially among HLA-DRB1*11(+) prostate cancer patients. Here, we performed in-depth investigation of the CD4(+) T cell response against the AE37 vaccine. We used the DR11/AE37 tetramer in combination with multicolor flow cytometry to identify and characterize AE37-specific CD4(+) T cells regarding memory and Tregs phenotype in HLA-DRB1*11(+) vaccinated patients. To verify vaccine-specific immunological memory in vivo, we also assessed AE37-specific CD4(+) T cells in defined CD4(+) memory subsets by cell sorting. Finally, vaccine-induced AE37-specific CD4(+) T cells were assessed regarding their functional profile. AE37-specific memory CD4(+) T cells could be detected in peptide-stimulated cultures from prostate cancer patients following vaccination even 4 y post-vaccination. The vast majority of vaccine-induced AE37-specific CD4(+) T cells exhibited a multifunctional, mostly Th1 cytokine signature, with the potential of granzyme B production. In contrast, we found relatively low frequencies of Tregs among AE37-specific CD4(+) T cells. This is the first report on the identification of vaccine-induced HER2-specific multifunctional long-lasting CD4(+) T cells in vaccinated prostate cancer patients.
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital , Athens, Greece.
Eleftheria A
EA
Anastasopoulou
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital , Athens, Greece.
Ioannis F
IF
Voutsas
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital , Athens, Greece.
Michael
M
Papamichail
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital , Athens, Greece.
Constantin N
CN
Baxevanis
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital , Athens, Greece.
Sonia A
SA
Perez
Antigen-specific memory CD4+ T-cells; MHC Class II tetramer; Tregs; cancer vaccines; prostate cancer